- Home
- ATAI vs ZBIO Comparison
ATAI vs ZBIO Comparison
Compare ATAI & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- ZBIO
- Stock Information
- Founded
- ATAI 2018
- ZBIO 2019
- Country
- ATAI Germany
- ZBIO United States
- Employees
- ATAI N/A
- ZBIO N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- ZBIO
- Sector
- ATAI Health Care
- ZBIO
- Exchange
- ATAI Nasdaq
- ZBIO NYSE
- Market Cap
- ATAI 282.6M
- ZBIO 389.2M
- IPO Year
- ATAI 2021
- ZBIO 2024
- Fundamental
- Price
- ATAI $1.41
- ZBIO $9.29
- Analyst Decision
- ATAI Strong Buy
- ZBIO Strong Buy
- Analyst Count
- ATAI 3
- ZBIO 7
- Target Price
- ATAI $10.50
- ZBIO $32.29
- AVG Volume (30 Days)
- ATAI 1.4M
- ZBIO 160.5K
- Earning Date
- ATAI 05-19-2025
- ZBIO 05-20-2025
- Dividend Yield
- ATAI N/A
- ZBIO N/A
- EPS Growth
- ATAI N/A
- ZBIO N/A
- EPS
- ATAI N/A
- ZBIO N/A
- Revenue
- ATAI $308,000.00
- ZBIO $5,000,000.00
- Revenue This Year
- ATAI $65.58
- ZBIO N/A
- Revenue Next Year
- ATAI N/A
- ZBIO N/A
- P/E Ratio
- ATAI N/A
- ZBIO N/A
- Revenue Growth
- ATAI N/A
- ZBIO N/A
- 52 Week Low
- ATAI $1.03
- ZBIO $5.83
- 52 Week High
- ATAI $2.57
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- ATAI 44.57
- ZBIO N/A
- Support Level
- ATAI $1.36
- ZBIO N/A
- Resistance Level
- ATAI $1.54
- ZBIO N/A
- Average True Range (ATR)
- ATAI 0.09
- ZBIO 0.00
- MACD
- ATAI -0.00
- ZBIO 0.00
- Stochastic Oscillator
- ATAI 0.00
- ZBIO 0.00
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.